a parallel, randomised, open-label clinical trial evaluating the safety and efficacy of methotrexate with apremilast in patients with moderate to severe palmoplantar psoriasis
Shilpadas ,Shazia ,G.Rajan ,Mojahidul Islam
» doi: http://https://ijpsl.co.in//.2021.v10.i01.pp01-011
Abstract
Various studies have revealed varying outcomes regarding the safety and effectiveness of
apremilast in comparison to methotrexate. Therefore, more research into the function of
Apremilast in palmoplantar psoriasis is required.Patients with moderate to severe palmoplantar
psoriasis were the subjects of a randomized, prospective, parallel-group, open-label trial. For 16
weeks, they were randomly assigned to either the methotrexate group (n = 19) or the apremilast
group (n = 22). Reduced scores on the modified palmoplantar psoriasis severity index (mPPPASI)
from week 0 to week 16 served as the primary effectiveness metric. Additional metrics included
the percentage of patients who achieved a Static Physician Global Assessment score of 0 (clear)
or 1 (almost clear), the percentage of patients who achieved mPPPASI75 (75% reduction in
mPPPASI score) by the end of 16 weeks, and the proportion of patients who demonstrated a
dermatology life quality index decline of at least 5àpoints from the beginning.At 16 weeks, there
was no statistically significant difference between the two groups in terms of m- PPPASI score
drop, however there was a significant decline from week 0 to week 16 within the group. The
secondary efficacy measures had identical outcomes. Out of the twenty-four adverse events
documented in the methotrexate group, three individuals had abnormal liver function tests. Out of
the 19 adverse events documented in the apremilast group, 2 patients had an infection of the upper
respiratory tract.In the treatment of moderate to severe palmoplantar psoriasis, apremilast is just
as effective as methotrexate, but it is more tolerable.Static Physician Global Assessment,
Dermatology Life Quality Index, Palmoplantar Psoriasis, Palmoplantar Psoriasis Area and
Severity Index, Apremilast